S&P 500   3,252.02 (-1.75%)
DOW   26,329.23 (-1.24%)
QQQ   267.97 (-3.05%)
AAPL   108.07 (-6.29%)
MSFT   200.65 (-1.99%)
FB   259.93 (-7.44%)
GOOGL   1,606.65 (+3.20%)
AMZN   3,026.84 (-5.74%)
TSLA   387.02 (-5.80%)
NVDA   496.09 (-4.77%)
BABA   304.74 (-2.50%)
CGC   18.67 (-0.59%)
GE   7.33 (-0.54%)
MU   49.88 (-1.19%)
AMD   74.71 (-4.24%)
T   26.80 (+0.15%)
F   7.66 (-3.04%)
ACB   4.04 (-1.22%)
GILD   57.80 (-1.25%)
NIO   30.64 (-4.22%)
NFLX   473.58 (-6.07%)
BA   142.92 (-3.62%)
DIS   119.80 (-1.43%)
S&P 500   3,252.02 (-1.75%)
DOW   26,329.23 (-1.24%)
QQQ   267.97 (-3.05%)
AAPL   108.07 (-6.29%)
MSFT   200.65 (-1.99%)
FB   259.93 (-7.44%)
GOOGL   1,606.65 (+3.20%)
AMZN   3,026.84 (-5.74%)
TSLA   387.02 (-5.80%)
NVDA   496.09 (-4.77%)
BABA   304.74 (-2.50%)
CGC   18.67 (-0.59%)
GE   7.33 (-0.54%)
MU   49.88 (-1.19%)
AMD   74.71 (-4.24%)
T   26.80 (+0.15%)
F   7.66 (-3.04%)
ACB   4.04 (-1.22%)
GILD   57.80 (-1.25%)
NIO   30.64 (-4.22%)
NFLX   473.58 (-6.07%)
BA   142.92 (-3.62%)
DIS   119.80 (-1.43%)
S&P 500   3,252.02 (-1.75%)
DOW   26,329.23 (-1.24%)
QQQ   267.97 (-3.05%)
AAPL   108.07 (-6.29%)
MSFT   200.65 (-1.99%)
FB   259.93 (-7.44%)
GOOGL   1,606.65 (+3.20%)
AMZN   3,026.84 (-5.74%)
TSLA   387.02 (-5.80%)
NVDA   496.09 (-4.77%)
BABA   304.74 (-2.50%)
CGC   18.67 (-0.59%)
GE   7.33 (-0.54%)
MU   49.88 (-1.19%)
AMD   74.71 (-4.24%)
T   26.80 (+0.15%)
F   7.66 (-3.04%)
ACB   4.04 (-1.22%)
GILD   57.80 (-1.25%)
NIO   30.64 (-4.22%)
NFLX   473.58 (-6.07%)
BA   142.92 (-3.62%)
DIS   119.80 (-1.43%)
S&P 500   3,252.02 (-1.75%)
DOW   26,329.23 (-1.24%)
QQQ   267.97 (-3.05%)
AAPL   108.07 (-6.29%)
MSFT   200.65 (-1.99%)
FB   259.93 (-7.44%)
GOOGL   1,606.65 (+3.20%)
AMZN   3,026.84 (-5.74%)
TSLA   387.02 (-5.80%)
NVDA   496.09 (-4.77%)
BABA   304.74 (-2.50%)
CGC   18.67 (-0.59%)
GE   7.33 (-0.54%)
MU   49.88 (-1.19%)
AMD   74.71 (-4.24%)
T   26.80 (+0.15%)
F   7.66 (-3.04%)
ACB   4.04 (-1.22%)
GILD   57.80 (-1.25%)
NIO   30.64 (-4.22%)
NFLX   473.58 (-6.07%)
BA   142.92 (-3.62%)
DIS   119.80 (-1.43%)
Log in
NASDAQ:CFMS

ConforMIS Stock Forecast, Price & News

$0.67
-0.03 (-4.04 %)
(As of 10/30/2020 03:27 PM ET)
Add
Compare
Today's Range
$0.67
Now: $0.67
$0.69
50-Day Range
$0.68
MA: $0.78
$0.88
52-Week Range
$0.50
Now: $0.67
$2.25
Volume900 shs
Average Volume591,728 shs
Market Capitalization$51.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Read More
ConforMIS logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CFMS
CUSIPN/A
Phone781-345-9001
Employees262

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.43 million
Book Value$0.24 per share

Profitability

Net Income$-28,480,000.00

Miscellaneous

Market Cap$51.78 million
Next Earnings Date11/4/2020 (Confirmed)
OptionableNot Optionable
$0.67
-0.03 (-4.04 %)
(As of 10/30/2020 03:27 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

How has ConforMIS's stock price been impacted by COVID-19 (Coronavirus)?

ConforMIS's stock was trading at $0.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CFMS shares have increased by 1.5% and is now trading at $0.67.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ConforMIS?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ConforMIS
.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ConforMIS
.

How can I listen to ConforMIS's earnings call?

ConforMIS will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were ConforMIS's earnings last quarter?

ConforMIS Inc (NASDAQ:CFMS) posted its earnings results on Wednesday, August, 5th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.04. The medical instruments supplier earned $19.47 million during the quarter, compared to analyst estimates of $14.65 million. ConforMIS had a negative return on equity of 189.07% and a negative net margin of 35.03%.
View ConforMIS's earnings history
.

What guidance has ConforMIS issued on next quarter's earnings?

ConforMIS issued an update on its third quarter 2020 Pre-Market earnings guidance on Tuesday, October, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $16.1-16.1 million, compared to the consensus revenue estimate of $13.02 million.

What price target have analysts set for CFMS?

4 brokers have issued 1 year price targets for ConforMIS's stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate ConforMIS's stock price to reach $2.33 in the next year. This suggests a possible upside of 248.3% from the stock's current price.
View analysts' price targets for ConforMIS
.

Are investors shorting ConforMIS?

ConforMIS saw a decrease in short interest in the month of September. As of September 30th, there was short interest totaling 577,500 shares, a decrease of 28.0% from the September 15th total of 802,500 shares. Based on an average trading volume of 502,200 shares, the days-to-cover ratio is currently 1.1 days.
View ConforMIS's Short Interest
.

Who are some of ConforMIS's key competitors?

What other stocks do shareholders of ConforMIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

Who are ConforMIS's key executives?

ConforMIS's management team includes the following people:
  • Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
  • Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
  • Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
  • Mr. Ed Kilgallen, VP of Operations
  • Ms. Lisa M. Donnelly, Sr. VP of Global Marketing

When did ConforMIS IPO?

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

Who are ConforMIS's major shareholders?

ConforMIS's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bourgeon Capital Management LLC (0.10%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Erin Henry, J Brent Alldredge, Mark A Augusti, Patricia A Davis and Paul S Weiner.
View institutional ownership trends for ConforMIS
.

Which institutional investors are buying ConforMIS stock?

CFMS stock was purchased by a variety of institutional investors in the last quarter, including Bourgeon Capital Management LLC.
View insider buying and selling activity for ConforMIS
.

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $0.67.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $51.96 million and generates $77.43 million in revenue each year. The medical instruments supplier earns $-28,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. ConforMIS employs 262 workers across the globe.

What is ConforMIS's official website?

The official website for ConforMIS is www.conformis.com.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.